Discovery of the first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor

Bioorg Med Chem Lett. 2014 Jun 1;24(11):2508-11. doi: 10.1016/j.bmcl.2014.04.004. Epub 2014 Apr 13.

Abstract

The Mycobacterium tuberculosis extracellular zinc metalloprotease 1 (Zmp1) has been proposed to play a key role in phagosome maturation and to enhance the survival of Mycobacterium tuberculosis in the host. Consequently, small molecule inhibitors of Zmp1 are of pivotal importance as a tool to better understand the pathogenicity of Zmp1 and as lead candidates for pharmacological intervention. Here we combined in silico structure-based inhibitor design with biochemical studies to discover and characterize the first potent competitive Zmp1 inhibitor showing a Ki of 94 nM and a high selectivity for Zmp1 with respect to human Neprilysin.

Keywords: Enzyme inhibitors; Metalloproteases; Tuberculosis; Virtual screening; Zmp1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Proteins / antagonists & inhibitors*
  • Bacterial Proteins / metabolism
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Humans
  • Metalloproteases / antagonists & inhibitors*
  • Metalloproteases / metabolism
  • Models, Molecular
  • Molecular Structure
  • Neprilysin / antagonists & inhibitors
  • Neprilysin / metabolism
  • Protease Inhibitors / chemical synthesis
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology*
  • Structure-Activity Relationship

Substances

  • Bacterial Proteins
  • Protease Inhibitors
  • Small Molecule Libraries
  • Metalloproteases
  • Zmp1 protein, Mycobacterium tuberculosis
  • Neprilysin